Pediatric antifungal therapy. Part II: neonatal infections.
The management of neonatal fungal infections poses several challenges, including the fact that the choices of available agents are limited, given the paucity of data relating to the use of newer antifungal agents in the group of infants. The information summarized herein represents in part the consensus of a group of clinicians involved in the care of neonates at risk of and with fungal infections. The document addresses the prophylaxis and treatment of fungal infections in neonates. It highlights the role of current and emerging antifungal agents, including the lipid amphotericin B products, echinocandins and triazoles.
Allen
U
U
Division of Infectious Diseases, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. upton.allen@sickkids.ca
Richardson
S
S
McGuire
W
W
Bow
E
E
Robinson
J
J
Rotstein
C
C
Doyle
J
J
Davies
D
D
Hui
C
C
Le Saux
N
N
Merchant
P
P
Laverdiere
M
M
Read
S
S
D000935:Antifungal Agents / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D009181:Mycoses / Q000188:drug therapy*
D000935:Antifungal Agents